SCHEMBL6003697

SCHEMBL6003697

Cc1ccc([C@@]23CNC(=O)[C@@H]2C3)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.51
SLC6A3 Q01959 2/20 0.51
SLC6A4 P31645 1/20 0.51
KCNH2 Q12809 1/20 0.51
MAOB P27338 4/20 0.38
MAOA P21397 2/20 0.38
CYP19A1 P11511 2/20 0.36
CRBN Q96SW2 2/20 0.34
CHRNA1 P02708 1/20 0.34
CHRNG P07510 1/20 0.34
CHRNB1 P11230 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA4 P43681 1/20 0.34
CHRND Q07001 1/20 0.34
DDB1 Q16531 1/20 0.34
SLC6A9 P48067 3/20 0.34
OPRM1 P35372 1/20 0.34
MGLL Q99685 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6003343 1.00 SLC6A2 (0.51) SLC6A2SLC6A3SLC6A4KCNH2MAOB
SCHEMBL14520916 1.00 SLC6A2 (0.51) SLC6A2SLC6A3SLC6A4KCNH2MAOB
SCHEMBL11642526 0.82 CACNA1F (0.36) KCNH2MAOBMAOAMEN1KMT2A
SCHEMBL16387061 0.82 CCR2 (0.36) SLC6A2SLC6A3SLC6A4KCNH2CYP19A1
SCHEMBL16383221 0.79 SLC6A2 (0.41) SLC6A2SLC6A3SLC6A4KCNH2MGLL
SCHEMBL14255639 0.79 SLC6A2 (0.41) SLC6A2SLC6A3SLC6A4KCNH2
SCHEMBL4194614 0.76 SLC6A4 (0.55) SLC6A2SLC6A3SLC6A4KCNH2
SCHEMBL8216844 0.76 SLC6A4 (0.55) SLC6A2SLC6A3SLC6A4KCNH2
SCHEMBL13698296 0.76 SLC6A4 (0.55) SLC6A2SLC6A3SLC6A4KCNH2
SCHEMBL4879280 0.76 SLC6A4 (0.55) SLC6A2SLC6A3SLC6A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060223875-A1 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes DOV PHARMACEUTICAL, INC. 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223875-A1 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes HTR1B, SLC6A3, CYP1B1 SLC6A2 14/4885SLC6A3 2/4885SLC6A4 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.